Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
- Registration Number
- NCT05760599
- Lead Sponsor
- Shi Ming
- Brief Summary
To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.
- Detailed Description
Atezolizumab plus bevacizumab is the first-line treatent for patients with advanced hepatocellular carcinoma. However, the second-line treatment is absent for patients who progressed on atezolizumab plus bevacizumab. Candonilimab is a humanized bisspecific monoclonal antibody against PD-1/ CTLA-4 IgG1. Candonilimab plus lenvatinib showed strong anti-tumor effect, with objective response of 44%. This single-arm, prospective, phase 2 trial is to explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 30
- The diagnosis of HCC was based on the diagnostic criteria for HCC used by the European Association for the Study of the Liver (EASL)
- Patients must have at least one tumor lesion that can be accurately measured according to EASL criteria.
- Barcelona clinic liver cancer-stage C
- Eastern Cooperative Oncology Group performance status of 0 to 2
- Patients have received atezolizumab plus bevacizumab and the tumor have progressed. Patients have not received other treatmets except for the atezolizumab plus bevacizumab.
- No Cirrhosis or cirrhotic status of Child-Pugh class A only
- Not amendable to surgical resection ,local ablative therapy and any other cured treatment.
- The following laboratory parameters:
Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥ 32 g/L ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) >1,500/mm3
• Ability to understand the protocol and to agree to and sign a written informed consent document
- Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy
- Known history of HIV
- History of organ allograft
- Known or suspected allergy to the investigational agents or any agent given in association with this trial.
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- Evidence of bleeding diathesis.
- Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.
- Known central nervous system tumors including metastatic brain disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Candonilimab Plus Bevacizumab Candonilimab Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week Candonilimab Plus Bevacizumab Bevacizumab Candonilimab 10mg/kg, Bevacizumab 15mg/kg, every 3 week
- Primary Outcome Measures
Name Time Method DCR per RECIST 1.1 12 months DCR （Disease Control Rate） include complete response, partial response and stable Disease per RECIST 1.1
- Secondary Outcome Measures
Name Time Method Overall survival (OS) 12 months OS is the length of time from the date of randomization until death from any cause.
ORR per RECIST 1.1 12 months Objective response rate (complete response+partial response) per RECIST 1.1
Progression free survival (PFS) 12 months PFS is defined as the time from the date of randomization to the date of the first objectively documented tumor progression or death due to any cause.
Biomarkers such as PD-L1 expression 12 months The blood specimen and needle biopsy specimen would be collected
Adverse events 30 days Safety will be evaluated according to the NCI CTCAE Version 4.03. All observations pertinent to the safety of the study medication will be recorded on the CRF and included in the final report.
Trial Locations
- Locations (1)
Cancer Center Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China